BACKGROUND AND PURPOSE: The pathogenesis of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains incompletely understood. It is generally assumed that it is caused by angiographic vasospasm. Our aim was to clarify the relationship among angiographic vasospasm, neurological worsening, cerebral infarction, and poor outcome and to investigate whether cerebral infarction also contributes to poor outcome by vasospasm-independent effects. METHODS: This exploratory analysis used data from 413 patients included in the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial. We studied the incidence of neurological worsening, cerebral infarction, and poor outcome in patients with and without angiographic vasospasm. Path analysis implemented by structural equation modeling was performed to determine direct and indirect path coefficients. RESULTS: Of the 194 patients with moderate to severe vasospasm, 43% had neurological worsening of any cause, 20% had cerebral infarction, and 46% poor outcome. Path coefficients for direct effects on poor outcome were 0.20 for World Federation of Neurological Surgeons Grade 4 to 5, 0.13 for history of hypertension, 0.19 for angiographic vasospasm, 0.16 for neurological worsening, and 0.11 for new cerebral infarction. Cerebral infarction contributed to poor outcome by vasospasm-dependent and -independent effects. CONCLUSIONS: Our data show that the majority of patients with moderate to severe angiographic vasospasm did not have neurological worsening of any cause or cerebral infarction. Besides, cerebral infarction also has a direct effect on outcome independent of angiographic vasospasm. This suggests that other coexisting factors might be involved in the pathogenesis of delayed cerebral ischemia, which should also be an important research target to improve outcome after subarachnoid hemorrhage.
BACKGROUND AND PURPOSE: The pathogenesis of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains incompletely understood. It is generally assumed that it is caused by angiographic vasospasm. Our aim was to clarify the relationship among angiographic vasospasm, neurological worsening, cerebral infarction, and poor outcome and to investigate whether cerebral infarction also contributes to poor outcome by vasospasm-independent effects. METHODS: This exploratory analysis used data from 413 patients included in the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial. We studied the incidence of neurological worsening, cerebral infarction, and poor outcome in patients with and without angiographic vasospasm. Path analysis implemented by structural equation modeling was performed to determine direct and indirect path coefficients. RESULTS: Of the 194 patients with moderate to severe vasospasm, 43% had neurological worsening of any cause, 20% had cerebral infarction, and 46% poor outcome. Path coefficients for direct effects on poor outcome were 0.20 for World Federation of Neurological Surgeons Grade 4 to 5, 0.13 for history of hypertension, 0.19 for angiographic vasospasm, 0.16 for neurological worsening, and 0.11 for new cerebral infarction. Cerebral infarction contributed to poor outcome by vasospasm-dependent and -independent effects. CONCLUSIONS: Our data show that the majority of patients with moderate to severe angiographic vasospasm did not have neurological worsening of any cause or cerebral infarction. Besides, cerebral infarction also has a direct effect on outcome independent of angiographic vasospasm. This suggests that other coexisting factors might be involved in the pathogenesis of delayed cerebral ischemia, which should also be an important research target to improve outcome after subarachnoid hemorrhage.
Authors: J Caspers; C Rubbert; B Turowski; D Martens; D C Reichelt; R May; J Aissa; D Hänggi; N Etminan; C Mathys Journal: Clin Neuroradiol Date: 2015-05-05 Impact factor: 3.649
Authors: Charlotte H P Cremers; Irene C van der Schaaf; Emerens Wensink; Jacoba P Greving; Gabriel J E Rinkel; Birgitta K Velthuis; Mervyn D I Vergouwen Journal: J Cereb Blood Flow Metab Date: 2013-11-27 Impact factor: 6.200
Authors: Georgia Korbakis; Shyam Prabhakaran; Sayona John; Rajeev Garg; James J Conners; Thomas P Bleck; Vivien H Lee Journal: Neurocrit Care Date: 2016-06 Impact factor: 3.210
Authors: Nefize Turan; Robert Allen-James Heider; Dobromira Zaharieva; Faiz U Ahmad; Daniel L Barrow; Gustavo Pradilla Journal: Transl Stroke Res Date: 2015-11-16 Impact factor: 6.829
Authors: Benjamin L Parker; Martin Røssel Larsen; Lars I H Edvinsson; Gro Klitgaard Povlsen Journal: J Cereb Blood Flow Metab Date: 2013-05-29 Impact factor: 6.200